URGN
URGN clinical trials: UroGen Pharma Ltd.
Every trial on ClinicalTrials.gov where UroGen Pharma Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 20
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
URGN on the catalyst calendar · URGN registry changes
- Primary completion Aug 2, 2029Sponsor estimatePhase 1NCT07725796A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBCUroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Bladder (Urothelial, Transitional Cell) CancerRecruitingURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2025ActualPhase 3NCT06331299A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerUroGen Pharma Ltd. · Bladder CancerCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimateNo phase registeredNCT05874921uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With JelmytoUroGen Pharma Ltd. · Urothelial CarcinomaRecruitingURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05494411Named Patient Program for Mitomycin for Pyelocalyceal SolutionUroGen Pharma Ltd. · Urothelial Cancer of Renal PelvisAvailableURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 3NCT06774131A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerUroGen Pharma Ltd. · Upper Urinary Tract Urothelial CarcinomaRecruitingURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2023ActualPhase 3NCT05243550A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerUroGen Pharma Ltd. · Bladder CancerActive, not recruitingURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2026ActualPhase 1NCT05375903A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)UroGen Pharma Ltd. · Non-muscle Invasive Bladder CancerCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2023ActualPhase 3NCT05136898Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)UroGen Pharma Ltd. · Bladder CancerCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2023ActualPhase 3NCT04688931A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerUroGen Pharma Ltd. · Bladder CancerTerminatedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 3, 2020ActualPhase 2NCT03558503A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerUroGen Pharma Ltd. · Bladder CancerCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2019ActualPhase 3NCT02793128The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC StudyUroGen Pharma Ltd. · Carcinoma, Transitional CellCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2020Sponsor estimatePhase 3NCT04006691Efficacy and Safety of UGN-101 in Recurrent PatientsUroGen Pharma Ltd. · CarcinomaWithdrawnURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2016Sponsor estimatePhase 1/Phase 2NCT02674269Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB...UroGen Pharma Ltd. · Overactive BladderWithdrawnURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2016ActualPhase 2NCT02307487Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC PatientsUroGen Pharma Ltd. · Bladder CancerCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualNo phase registeredNCT01803295Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBCUroGen Pharma Ltd. · Carcinoma of Urinary Bladder, SuperficialCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualNo phase registeredNCT02891460Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC PatientsUroGen Pharma Ltd. · Urinary Bladder NeoplasmsCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 1/Phase 2NCT01997983Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC PatientsUroGen Pharma Ltd. · Interstitial CystitisCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2015ActualPhase 1/Phase 2NCT02179099Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB PatientsUroGen Pharma Ltd. · Overactive BladderTerminatedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013ActualNo phase registeredNCT01799499A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C...UroGen Pharma Ltd. · Non Muscle Invasive Bladder CancerWithdrawnURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualNo phase registeredNCT01648010Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device...UroGen Pharma Ltd. · Carcinoma of Urinary Bladder, InvasiveCompletedURGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT02701023Compassionate Use of MitoGel in Upper Tract Urothelial CarcinomaJonsson Comprehensive Cancer Center · Urothelial Carcinoma Ureteral LocationNo longer availableURGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner